HLA Antibody Detection via Solid-Phase Substrates
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for transplant rejection screening, such as cell-based assays, fail to detect antibodies specific for denatured HLA antigens, which can lead to false positives and negatives, and do not account for the clinical significance of these antibodies in transplant rejection, resulting in potential organ rejection and misallocation.
Innovation Solution
Developing methods to screen for HLA antibodies using solid-phase substrates that present both native and denatured HLA antigens, allowing for the separation and detection of antibodies specific to each conformation, thereby distinguishing between native and denatured antigen reactivity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If cell-based assays are used to screen for HLA antibodies, then the assay is simple to perform, but antibodies specific for denatured HLA antigens cannot be detected
Solution Approach 1:
The assay is divided into separate stages: first, solid-phase substrates are used to capture antibodies against denatured HLA antigens; then, native HLA antigens are used to detect antibodies against native conformation. This segmentation allows detection of both antibody types that were previously missed by single-method approaches.
Solution Approach 2:
Solid-phase substrates serve as intermediaries to present denatured HLA antigens in a controlled manner, enabling antibody detection without requiring live cells. This intermediary approach bridges the gap between simplicity and detection capability.
2Reliability
If only native HLA antigens are screened, then the screening process is straightforward, but false positives and negatives occur due to undetected denatured antigen antibodies
Solution Approach 1:
The assay performs preliminary detection of antibodies against denatured HLA antigens using solid-phase substrates before proceeding to native antigen screening. This preliminary action prevents false positives and negatives by identifying all relevant antibodies in advance.
Solution Approach 2:
The patent changes the conformational parameter of HLA antigens from native to denatured state on solid-phase substrates, enabling detection of a different antibody subset. This parameter change expands the detection scope without compromising screening efficiency.
3Measurement precision
If solid-phase substrates presenting both native and denatured antigens are used, then comprehensive antibody detection is achieved, but the assay complexity increases
Solution Approach 1:
The solid-phase substrate system is designed to perform multiple functions: capturing antibodies against denatured antigens, presenting native antigens, and enabling differentiated detection. This multi-functionality achieves comprehensive detection while maintaining operational simplicity through a unified platform.
4Ease of manufacture
If antibodies against denatured HLA antigens are not distinguished from native antigen antibodies, then the assay remains simple, but transplant rejection risk increases
Solution Approach 1:
The assay applies local quality differentiation by using distinct solid-phase substrates with specific properties: one set presents denatured antigens to capture specific antibodies, while another set presents native antigens. This local differentiation enables precise identification of antibody specificity, reducing transplant rejection risk.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enhances the accuracy of transplant matching by identifying antibodies reactive to denatured HLA antigens, reducing the risk of transplant rejection and improving organ allocation by providing a more comprehensive HLA antibody profile.
Implementation Method 1
detecting binding of an antibody to the panel, wherein binding of an antibody to a solid-phase substrate presenting a denatured HLA antigen is indicative of a human subject having antibodies specific for a selected denatured HLA antigen
Data Source
AI summary
The invention is directed to methods of screening for HLA antibodies comprising detecting antibodies specific for native HLA antigens and denatured HLA antigens. The invention also provides for methods of removing antibodies specific for denatured HLA antigens or antibodies specific for native HLA antigens from a serum sample. In addition, the invention also provides for method of predicting whether a transplant recipient has an increased risk for rejecting the transplanted organ.